15th Conference on Retroviruses and Opportunistic Infections
February 3-8, 2008
February 9, 2008
Durable Efficacy and Safety With Isentress Treatment
Year-long follow-up data from two Phase III clinical trials of Isentress were reported this week at the 15th CROI, confirming that the drug offers durable antiretroviral activity to those in need of new treatment options.
Good Bacteria Reduces Vaginal HIV Levels Healthy bacteria (Lactobacillus) limits the amount of HIV detected in the genital secretions of women infected with the virus, Seattle and Rochester researchers report.
February 12, 2008
Women & HIV Treatment
Regan Hofmann talks with Judith Currier, MD, about treatment and research advances in women living with HIV, and learns that many women are doing quite well.
Condom-Free Sex? Controversial Swiss Declaration
Regan Hofmann talks with Bernard Hirschel, MD, of the University Hospital, Geneva, Switzerland about a controversial Swiss position paper declaring that HIV-positive people with undetectable viral loads cannot transmit HIV.
February 11, 2008
New Hope for Treatment Experienced
David Evans talks
with UCLA researcher, David Hardy, MD, about the latest data on antiretroviral options for people who are heavily treatment experienced and learns that the treatment landscape has changed radically.
February 8, 2008
HIV & Your Heart: Part I
David Evans talks with St. Luke’s Roosevelt’s Donald Kotler, MD about the role of inflammation in heart disease and surprising research on Ziagen and heart attacks.
February 6, 2008
Refining HIV Treatment for New Med Takers
David Evans talks with Los Angeles HIV specialist, David Hardy, MD, about research to refine and enhance treatment for people taking HIV medications for the first time.